Parnax Lab (506128)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 56.49% and profit growth of 200.83% show strong recent momentum.
• Trailing P/E of 11.22 and PEG of 0.09 suggest the market is not fully pricing in growth.
• Piotroski F-Score of 7/9 indicates reasonably solid fundamentals.
• Latest quarter sales of ₹63 Cr and net profit of ₹3 Cr annualize to roughly ₹12 Cr, supporting the modest market cap.

Concerns

• ROE is only 6.02% despite a P/B of 4.79 — paying 4.8 times book for a low return on equity is unattractive.
• Stock trades below its 52-week low of ₹99.20 and far below the ₹182 high, implying weak price momentum or unresolved issues.
• No dividend, and missing debt/equity and promoter holding data reduce transparency.
• 200.83% profit growth on a small base could be unsustainable or partly a base effect.

AI Analysis

At ₹94.80, Parnax Lab is a small pharmaceutical company with a ₹109 Cr market cap. The headline numbers look superficially intriguing: a P/E of 11.22, 56.49% sales growth, 200.83% profit growth, and a Piotroski F-Score of 7/9. But I have to stop and ask: what is the quality of these earnings? A P/B of 4.79 against a book value of ₹19.80 means the market is paying a hefty premium for this business, yet ROE is only 6.02%. That is a combination that does not normally endear me to a company — high valuation relative to tangible assets and low return on equity. ROCE of 13.97% is respectable but not exceptional, especially for pharmaceuticals. No dividend means shareholder returns depend entirely on capital appreciation. The 52-week range is telling: the stock trades at ₹94.80, below the stated low of ₹99.20, after falling from ₹182. That is a nearly 48% drawdown from the high. A PEG of 0.09 usually screams cheap only if the growth is durable; with a 200% profit jump off a small base, I view that with suspicion. Latest quarter sales were ₹63 Cr and net profit ₹3 Cr — that would annualize to roughly ₹12 Cr, around 9 times the market cap, so the growth is real in the numbers. But I cannot ignore that reported trailing P/E is 11.22, book value growth is not matching the profit jump, and debt/equity and promoter holding data are missing. Without those, I cannot properly assess financial risk or alignment with minority shareholders. This is an interesting fast grower, but it is not obviously a wonderful business at a fair price. I need more evidence of durable competitive advantage, consistent capital allocation, and honest margins. In Buffett's words, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. I need to see more before calling this wonderful.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer